Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Inclusion Criteria:

1. Ages 18 years or older;
2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
3. Life expectancy no less than 12 weeks;
4. Pathologically confirmed advanced solid tumor or relapsed/refractory lymphoma with measurable target lesions;
5. Adequate bone marrow, haptic, renal and coagulation function.

Exclusion Criteria:

1. Evidence of central nervous system (CNS) involvement;
2. Previously treated with similar agents;
3. History of anticancer treatment within 4 weeks of enrollment (6 weeks for subjects treated with nitrosoureas or mitomycins);
4. Anticipated to be involved in other anti-cancer treatments expect for palliative care during the trial;
5. History of anti-cancer vaccination; or history of vaccination using attenuated vaccines within 4 weeks of enrollment;
6. History of Red blood cell (RBC) transfusion within or treatment with erythropoitin(EPO) within 3 months of enrollment;
7. History of grade 3 or higher thrombolic incidence within 2 years of enrollment, or using antithrombotic/anticoagulant agents;
8. With confirmed immunodeficiency, uncontrolled auto-immune disease, uncontrolled cardiovascular disease, uncontrolled or active infection;
9. Substance abuse.